https://transhumanist.ru/index.php?action=history&feed=atom&title=CCL18 2026-06-13T17:03:53Z История изменений этой страницы в вики MediaWiki 1.43.6 https://transhumanist.ru/index.php?title=CCL18&diff=6075&oldid=prev 2021-05-12T15:10:01Z

<p>Новая страница: «C-C motif chemokine 18 precursor (Alternative macrophage activation-associated CC chemokine 1) (AMAC-1) (CC chemokine PARC) (Dendritic cell chemokine 1) (DC-CK1)...»</p> <p><b>Новая страница</b></p><div>C-C motif chemokine 18 precursor (Alternative macrophage activation-associated CC chemokine 1) (AMAC-1) (CC chemokine PARC) (Dendritic cell chemokine 1) (DC-CK1) (Macrophage inflammatory protein 4) (MIP-4) (Pulmonary and activation-regulated chemokine) (Small-inducible cytokine A18) [Contains: CCL18(1-68); CCL18(3-69); CCL18(4-69)] [AMAC1] [DCCK1] [MIP4] [PARC] [SCYA18]<br /> <br /> ==Publications==<br /> <br /> {{medline-entry<br /> |title=Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.<br /> |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30685456<br /> |abstract=Atopic dermatitis (AD) shows differential clinical presentation in older compared with younger patients. Nevertheless, changes in the AD molecular profile with age are unknown. We sought to characterize age-related changes in the AD profile. We evaluated age-specific changes in lesional and nonlesional tissues and blood from patients with moderate-to-severe AD (n = 246) and age-matched control subjects (n = 71) using immunohistochemistry, quantitative real-time PCR, and Singulex in a cross-sectional study. Patients were analyzed by age group (18-40, 41-60, and ≥61 years). Although disease severity/SCORAD scores were similar across AD age groups (mean, approximately 60 years; P = .873), dendritic cell infiltrates (CD1b and FcεRI , P &lt; .05) decreased with age. T 2 measures (IL5, [[IL13]], [[CCL13]], [[CCL18]], and CCL26) significantly decreased with age in patients with AD, despite increasing with age in control subjects. Consistent with T 2 axis decreases, serum IgE levels and eosinophil counts negatively correlated with age in patients with AD (r = -0.24 and r = -0.23, respectively; P &lt; .05). T 22-secreted [[IL22]] expression levels also decreased with age uniquely in patients with AD (P &lt; .05). Expression of T 1-related (IFNG, IL12/23p40, [[STAT1]], and CXCL9; P &lt; .05 for CXCL9) and T 17-related (IL17A and IL20; P &lt; .05 for IL20) markers increased with age in both patients with AD and control subjects. Expression of terminal differentiation measures significantly increased in older patients with AD (loricrin [LOR] and filaggrin [FLG], P &lt; .05), whereas expression of S100As (S100A8, P &lt; .01) and hyperplasia markers (epidermal thickness, keratin 16, and Ki67; P &lt; .05 for keratin 16) decreased. Serum trends in AD mimicked skin findings, with T 2 downregulation (CCL26; r = -0.32, P &lt; .1) and T 1 upregulation (IFN-γ; r = 0.48, P &lt; .01) with age. The adult AD profile varies with age. Although T 1/T 17 skewing increases in both patients with AD and control subjects, patients with AD show unique decreases in T 2/T 22 polarization and normalization of epithelial abnormalities. Thus age-specific treatment approaches might be beneficial for AD.<br /> |mesh-terms=* Adolescent<br /> * Adult<br /> * Aged<br /> * Aged, 80 and over<br /> * Aging<br /> * Cytokines<br /> * Dermatitis, Atopic<br /> * Female<br /> * Gene Expression<br /> * Humans<br /> * Male<br /> * Middle Aged<br /> * Phenotype<br /> * Severity of Illness Index<br /> * Skin<br /> * Young Adult<br /> |keywords=* Atopic dermatitis<br /> * T(H)1<br /> * T(H)17<br /> * T(H)2<br /> * T(H)22<br /> * aging<br /> * biomarker<br /> * filaggrin<br /> * hyperplasia<br /> * loricrin<br /> * skin<br /> |full-text-url=https://sci-hub.do/10.1016/j.jaci.2019.01.015<br /> }}</div>

OdysseusBot